Market Insight - Originator/generic competition: who's the 'bad guy'?
This article was originally published in Scrip
Intellectual property rights are key elements of the fierce competition between originator and generics companies. Patents are central because it is only when patents elapse that generic products can enter the market. This is when competition in the market begins. Trademarks, trade dress and other marketing tools then come into play. Xavier Buffet Delmas and Laura Morelli explain some interesting recent legal developments linked to this battle.
You may also be interested in...
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.
Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.
Nearly 500 shipments of illegal and unapproved prescription drugs and combination medical devices were seized at US borders thanks to Operation Broadsword.